Using Remote Monitoring to Address Health Disparities in Type 2 Diabetes
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- В протоколе указаны: Blood glucose monitor with Digital Platform and Health Coaching, Continuous glucose monitor, Usual Care.
- Кому может быть актуально
- Состояния в реестре: Diabetes Mellitus, Type 2. Базовые параметры: от 18 лет · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- США
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Официальное название
Randomized Controlled Trial Using Remote Monitoring With an Automated Patient Engagement System and a Self-Monitoring Program With Continuous Glucose Monitors to Address Health Disparities in Type 2 Diabetes
Обзор
Patient populations at community health centers, specifically Black or African American and Hispanic or Latino populations with Type 2 diabetes, experience significant health disparities. In particular, they have higher rates of diabetes-related complications and other related conditions such as myocardial infarction, cerebrovascular disease, kidney failure, blindness, neuropathy, and the risk of amputation. Diabetes affects 34 million adults in the US. Achieving a target HbA1c less than 8% can be challenging through diabetes management. Patients are able to monitor their blood glucose levels with devices such as blood glucose meters or continuous glucose monitors to facilitate diabetes management and glycemic control. Past studies have demonstrated that these devices are effective in engaging patients in the improvement of diabetes management. Current advancements in remote patient monitoring and self-monitoring have been observed to be effective in facilitating improvement in diabetes outcomes. However, the effectiveness and financial feasibility of these devices delivered in conjunction with automated patient engagement systems in remote patient monitoring programs is not well understood among underinsured, underserved, and vulnerable minority populations as they face a high-cost barrier particularly with continuous glucose monitors. To better address this gap in knowledge, this pilot study will compare and examine the effectiveness of these interventions on patient outcomes with Type 2 diabetes among populations in the West Side of Chicago. Study the comparative effectiveness among patients with uncontrolled Type 2 diabetes on insulin in an intervention group using remote patient monitoring and automated patient engagement system with blood glucose monitors to a group using a self-monitoring program with continuous glucose monitors and a usual care group receiving standard care. Conduct a feasibility analysis and financial impact of these programs among an underinsured and underserved population of Black/African Americans or Hispanic/Latinos with Type 2 diabetes.
Подробное описание
This will be conducted at a Lawndale Christian Health Center, a community health center in the West Side of Chicago that serves a largely Black or African American and Hispanic or Latino population. To accomplish this objective, Aim 1 will study the impact on patients with uncontrolled Type 2 diabetes on insulin by comparing an intervention group that features remote patient monitoring with an automated patient engagement system and health coaching using blood glucose meters compared to a group that features a self-monitoring program using continuous glucose monitoring devices and a usual care group with standard care, and Aim 2 will examine the feasibility of implementing these interventions and financial impact of each treatment group at a community health center. To understand the effect of this study on health outcomes, patient level data will be examined including primary outcomes for health measurements such as HbA1c, blood glucose, BMI/weight, estimated glomerular filtration rate (eGFR), patient-reported outcomes including medication adherence, daily activities, diabetes self-management activities, and secondary outcomes for health measurements such as LDL cholesterol, systolic and diastolic blood pressures, as well as implementation outcomes such as acceptability, appropriateness, and feasibility. The costs of implementation and delivery will be examined using a budget impact analysis. This study will be essential for informing the impact on health disparities through remote monitoring with automated patient engagement compared to self-monitoring when providing care for underinsured and underserved populations.
Вмешательства
- Устройство Blood glucose monitor with Digital Platform and Health Coaching
Blood glucose monitors will be used daily to measure blood glucose measurements. - Устройство Continuous glucose monitor
Continuous glucose monitors will be used daily to measure blood glucose measurements. - Другое Usual Care
Usual care for type 2 diabetes
Первичные конечные точки
- Glycated Hemoglobin [Срок оценки: Baseline and at 4 Months]
- Blood Glucose [Срок оценки: 4 Months]
- Engagement with digital platform with a daily submission of blood glucose [Срок оценки: 4 Months]
- Implementation - Acceptability of Intervention Measure (AIM) [Срок оценки: Baseline and at 4 Months]
- Implementation - Intervention Appropriateness Measure (IAM) [Срок оценки: Baseline and at 4 Months]
- Implementation - Feasibility of Intervention Measure (FIM) [Срок оценки: Baseline and at 4 Months]
- The Diabetes Self-Management Questionnaire (DSMQ) on eating, medication, glucose monitoring, physical activity, and healthcare use [Срок оценки: Baseline and at 4 Months]
Вторичные конечные точки (8)
- Weight [Срок оценки: Baseline and at 4 Months]
- Height [Срок оценки: Baseline and at 4 Months]
- Estimated glomerular filtration rate [Срок оценки: Baseline and at 4 Months]
- Low-density lipoprotein Cholesterol [Срок оценки: Baseline and at 4 Months]
- Blood Pressure [Срок оценки: Baseline and at 4 Months]
- Clinic Visit [Срок оценки: 4 Months]
- Hospitalizations [Срок оценки: 4 Months]
- Costs of Implementation [Срок оценки: 4 Months]
Критерии участия
Критерии включения
- 18 years of age or older
- Have an assigned primary care provider
- Diagnosis of Type 2 diabetes
- Medication use is insulin
- HbA1c of 8.0% or higher
Критерии исключения
- Diagnosis of chronic kidney disease at Stage 4 or higher
- Diagnosis of pregnancy
- Diagnosis of behavioral health conditions including serious mental illness or severe depression in the past 6 months.
- All participants must have a smartphone that is able to access internet services.
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Нет
Дизайн исследования
- Распределение
- Рандомизированное
- Модель
- Факторный дизайн
- Маскирование
- Открытое
- Основная цель
- Профилактика
Центры проведения
США · 1 центр
- Lawndale Christian Health Center — Chicago
Публикации
- Weinstock RS, Aleppo G, Bailey TS, Bergenstal RM, Fisher WA, Greenwood DA, Young LA. The Role of Blood Glucose Monitoring in Diabetes Management. Arlington (VA): American Diabetes Association; 2020 Oct. Available from http://www.ncbi.nlm.nih.gov/books/NBK566165/ PMID 33411424
- Schmitt A, Gahr A, Hermanns N, Kulzer B, Huber J, Haak T. The Diabetes Self-Management Questionnaire (DSMQ): development and evaluation of an instrument to assess diabetes self-care activities associated with glycaemic control. Health Qual Life Outcomes. 2013 Aug 13;11:138. doi: 10.1186/1477-7525-11-138. PMID 23937988
- Weiner BJ, Lewis CC, Stanick C, Powell BJ, Dorsey CN, Clary AS, Boynton MH, Halko H. Psychometric assessment of three newly developed implementation outcome measures. Implement Sci. 2017 Aug 29;12(1):108. doi: 10.1186/s13012-017-0635-3. PMID 28851459
Идентификаторы
NCT: NCT06517576 · LCHC-ID-10 · P30DK092949